Vivus Hopes Second Time's a Charm for Qnexa in Obesity
WASHINGTON – Armed with more information about cardiovascular and teratogenic risks, as well as a less restrictive risk evaluation and mitigation strategy (REMS), Vivus Inc. is prepared for a second performance before the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC).
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST